Hugh M. Cole

SVP, Chief Business Officer, ARIAD Pharmaceuticals.

Companies

Catabasis PharmaceuticalsBoard member Jul 30, 2019 to now¹
Jounce TherapeuticsChief operating officer Aug 3, 2022 to Jan 11, 2023²
Jounce TherapeuticsChief Business Officer Dec 21, 2017 to Mar 17, 2022³
ARIAD PharmaceuticalsSVP, Chief Business Officer Apr 8, 2014 to Feb 16, 2017⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Jounce Therapeutics JNCE110,082 shares⁵Jan 10, 2023

As of each latest filing. The line shows shares held over time.

Recent filings

Jan 10, 2023Sold 9,182 shares at $1.12 of Jounce Therapeutics⁵
Jan 9, 2023Sold 7,452 shares at $1.10 of Jounce Therapeutics⁵
Aug 1, 2022Granted 20,000 shares of Jounce Therapeutics⁶
Feb 1, 2022Granted 42,500 shares of Jounce Therapeutics⁷
Jan 10, 2022Sold 6,205 shares at $6.65 of Jounce Therapeutics⁸
Jan 7, 2022Sold 3,468 shares at $7.30 of Jounce Therapeutics⁸

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCatabasis Pharmaceuticals, Board member
2
SEC EDGARJounce Therapeutics, Chief operating officer
3
SEC EDGARJounce Therapeutics, Chief Business Officer
4
SEC EDGARARIAD Pharmaceuticals, SVP, Chief Business Officer
5
SEC EDGARJounce Therapeutics shares after the filing of Jan 10, 2023
6
SEC EDGARForm 4 filed Aug 3, 2022
7
SEC EDGARForm 4 filed Feb 3, 2022
8
SEC EDGARForm 4 filed Jan 11, 2022